Eu(DPM)3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Eu(DPM)3
• 英文别名: Resolve-A1；europium;2,2,6,6-tetramethylheptane-3,5-dione
• 化学式: C₃₃H₆₀EuO₆
• 分子量: 704.796
• InChiKey: LTMLYJXKFUNAJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.82
• 重原子数：
  40
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Eu(DPM)3 、 二-n-己基亚砜 以 乙醇 为溶剂， 生成 Eu(DPM)3(DHSO)
  参考文献：
  名称：

  Karasev, V. E.; Botova, I. N.; Kovalenko, V. N., Russian Journal of Inorganic Chemistry, 1988, vol. 33, p. 637 - 640

  摘要：

  DOI：

文献信息

• CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20140088117A1

  公开（公告）日：2014-03-27

  Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的环氧杂环基卡氧酰胺化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，其中R2是环氧杂环基，X是噻唑基、吡嗪基、吡啶基或嘧啶基，可用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I中的化合物进行哺乳动物细胞中的体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。
• Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds And Methods Of Use
  申请人：Genentech, Inc.

  公开号：US20160213652A1

  公开（公告）日：2016-07-28

  Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的环氧杂环基卡氧酰胺化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，其中R2是环氧杂环基，X是噻唑基、吡嗪基、吡啶基或嘧啶基，可用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I中的化合物进行哺乳动物细胞中的体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
  申请人：Genentech, Inc.

  公开号：US09328106B2

  公开（公告）日：2016-05-03

  Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的环氧杂环基羧酰胺化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，其中R2是一个环氧杂环基，X是噻唑基、吡嗪基、吡啶基或嘧啶基，用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。本文介绍了利用公式I中的化合物在哺乳动物细胞中进行体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• PREPARATION AND CHARACTERIZATION OF SOME RARE-EARTH COMPLEXES OF THE PHTHALOCYANINE RADICAL
  作者：Hiroshi Sugimoto、Teruaki Higashi、Masayasu Mori

  DOI：10.1246/cl.1983.1167

  日期：1983.8.5

  5-heptanedionato) complexes of rare-earth elements, M3+(dpm)3 (M = Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, and Y) with lithium phthalocyanine Li2(Pc2−) in tetrahydrofuran gave new stable phthalocyanine radical complexes [M3+(Pc−·)(dpm)2].

  稀土元素三(2,2,6,6-四甲基-3,5-庚二酮)配合物的反应，M3+(dpm)3 (M = Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er、Tm、Yb、Lu 和 Y) 与四氢呋喃中的锂酞菁 Li2(Pc2-) 生成新的稳定的酞菁自由基复合物 [M3+(Pc-·)(dpm)2]。